These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 38753041)

  • 1. Non-invasive biomarkers prognostic of decompensation events in NASH cirrhosis: a systematic literature review.
    Amoroso M; Augustin S; Moosmang S; Gashaw I
    J Mol Med (Berl); 2024 Jul; 102(7):841-858. PubMed ID: 38753041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive fibrosis tools in NAFLD: validation of APRI, BARD, FIB-4, NAFLD fibrosis score, and Hepamet fibrosis score in a Portuguese population.
    Rigor J; Diegues A; Presa J; Barata P; Martins-Mendes D
    Postgrad Med; 2022 May; 134(4):435-440. PubMed ID: 35332833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Noninvasive biomarkers in predicting nonalcoholic steatohepatitis and assessing liver fibrosis: systematic review and meta-analysis.
    Ismaiel A; Leucuta DC; Popa SL; Fagoonee S; Pellicano R; Abenavoli L; Dumitrascu DL
    Panminerva Med; 2021 Dec; 63(4):508-518. PubMed ID: 33165307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of the accuracy of the FAST™ score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms.
    Woreta TA; Van Natta ML; Lazo M; Krishnan A; Neuschwander-Tetri BA; Loomba R; Mae Diehl A; Abdelmalek MF; Chalasani N; Gawrieh S; Dasarathy S; Vuppalanchi R; Siddiqui MS; Kowdley KV; McCullough A; Terrault NA; Behling C; Kleiner DE; Fishbein M; Hertel P; Wilson LA; Mitchell EP; Miriel LA; Clark JM; Tonascia J; Sanyal AJ;
    PLoS One; 2022; 17(4):e0266859. PubMed ID: 35427375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of liver fibrosis using non-invasive screening tools in individuals with diabetes mellitus and metabolic syndrome.
    Shaji N; Singhai A; Joshi R
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease.
    Qadri S; Ahlholm N; Lønsmann I; Pellegrini P; Poikola A; Luukkonen PK; Porthan K; Juuti A; Sammalkorpi H; Penttilä AK; D'Ambrosio R; Soardo G; Leeming DJ; Karsdal M; Arola J; Kechagias S; Pelusi S; Ekstedt M; Valenti L; Hagström H; Yki-Järvinen H
    J Clin Endocrinol Metab; 2022 Apr; 107(5):e2008-e2020. PubMed ID: 34971370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers.
    Vilar-Gomez E; Chalasani N
    J Hepatol; 2018 Feb; 68(2):305-315. PubMed ID: 29154965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does the FT3-to-FT4 ratio easily predict the progression of NAFLD and NASH cirrhosis?
    Türker F; Oral A; Şahin T; Türker BÇ; Koçak E; Ataoğlu HE; Ahbab S
    J Int Med Res; 2021 Nov; 49(11):3000605211056841. PubMed ID: 34763561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low liver fat in non-alcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality.
    Lee SW; Huang DQ; Bettencourt R; Ajmera V; Tincopa M; Noureddin N; Amangurbanova M; Siddiqi H; Madamba E; Majzoub AM; Nayfeh T; Tamaki N; Izumi N; Nakajima A; Yoneda M; Idilman R; Gumussoy M; Oz DK; Erden A; Loomba R
    Aliment Pharmacol Ther; 2024 Jan; 59(1):80-88. PubMed ID: 37968251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran.
    Amernia B; Moosavy SH; Banookh F; Zoghi G
    BMC Gastroenterol; 2021 Dec; 21(1):453. PubMed ID: 34861841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comprehensive review of noninvasive liver fibrosis tests in pediatric nonalcoholic Fatty liver disease.
    Mansoor S; Collyer E; Alkhouri N
    Curr Gastroenterol Rep; 2015 Jun; 17(6):23. PubMed ID: 26031832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease.
    Arora A; Sharma P
    J Clin Exp Hepatol; 2012 Jun; 2(2):145-55. PubMed ID: 25755423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial.
    Brown EA; Minnich A; Sanyal AJ; Loomba R; Du S; Schwarz J; Ehman RL; Karsdal M; Leeming DJ; Cizza G; Charles ED
    JHEP Rep; 2023 Apr; 5(4):100661. PubMed ID: 36866389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis.
    Chalasani N; Abdelmalek MF; Loomba R; Kowdley KV; McCullough AJ; Dasarathy S; Neuschwander-Tetri BA; Terrault N; Ferguson B; Shringarpure R; Shapiro D; Sanyal AJ
    Liver Int; 2019 May; 39(5):924-932. PubMed ID: 30253043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes.
    Bril F; McPhaul MJ; Caulfield MP; Clark VC; Soldevilla-Pico C; Firpi-Morell RJ; Lai J; Shiffman D; Rowland CM; Cusi K
    Diabetes Care; 2020 Feb; 43(2):290-297. PubMed ID: 31604692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified AST to platelet ratio index improves APRI and better predicts advanced fibrosis and liver cirrhosis in patients with non-alcoholic fatty liver disease.
    Huang C; Seah JJ; Tan CK; Kam JW; Tan J; Teo EK; Kwek A; Wong YJ; Tan M; Ang TL; Kumar R
    Clin Res Hepatol Gastroenterol; 2021 Jul; 45(4):101528. PubMed ID: 33268036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population.
    Nielsen MJ; Leeming DJ; Goodman Z; Friedman S; Frederiksen P; Rasmussen DGK; Vig P; Seyedkazemi S; Fischer L; Torstenson R; Karsdal MA; Lefebvre E; Sanyal AJ; Ratziu V
    J Hepatol; 2021 Dec; 75(6):1292-1300. PubMed ID: 34454994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The NAFLD Decompensation Risk Score: External Validation and Comparison to Existing Models to Predict Hepatic Events in a Retrospective Cohort Study.
    Ahmed HS; Gangasani N; Jayanna MB; Long MT; Sanchez A; Murali AR
    J Clin Exp Hepatol; 2023; 13(2):233-240. PubMed ID: 36950488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
    Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.